Compare NMG & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMG | TTRX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.1M | 298.8M |
| IPO Year | 2015 | 2025 |
| Metric | NMG | TTRX |
|---|---|---|
| Price | $0.88 | $10.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $3.62 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 477.2K | 90.0K |
| Earning Date | 11-11-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $900.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $2.57 |
| 52 Week High | $3.60 | $16.45 |
| Indicator | NMG | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 17.04 | 38.98 |
| Support Level | N/A | $9.02 |
| Resistance Level | $2.42 | $10.72 |
| Average True Range (ATR) | 0.05 | 0.89 |
| MACD | -0.01 | -0.27 |
| Stochastic Oscillator | 5.25 | 7.76 |
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.